- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00380029
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
A Phase II Study of Erlotinib (Tarceva®) in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving erlotinib after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well erlotinib works when given before and after surgery in treating patients with muscle-invasive bladder cancer.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine the effect of neoadjuvant erlotinib hydrochloride on histopathological, molecular, and genetic correlates in patients undergoing radical cystectomy for muscle-invasive bladder cancer.
Secondary
- Determine the pathological complete response rate in surgical specimens from patients treated with this drug.
- Determine recurrence and progression rates after cystectomy (up to 2 years after surgery) in patients treated with neoadjuvant and adjuvant erlotinib hydrochloride.
- Determine 2- and 5-year disease-free, disease-specific, and overall survival rates in patients treated with this drug.
- Determine the safety of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive oral erlotinib hydrochloride once daily for 4 weeks. Patients then undergo radical cystectomy with curative intent. Within 12 weeks after surgery, patients resume oral erlotinib hydrochloride* once daily for up to 2 years in the absence of disease progression or unacceptable toxicity.
Note: *Patients who are candidates for adjuvant chemotherapy (e.g., found to have pathologic stage T3 (pT3), Node positive (N+) disease) do not receive erlotinib hydrochloride after surgery.
Tumor tissue is obtained at baseline (at the original or confirmatory transurethral resection of the bladder tumor) and at the time of cystectomy for analysis of drug-specific and tissue-based biomarkers by western blot, immunohistochemistry, and gene array techniques. Histopathological, molecular, and genetic correlates are analyzed to better understand the potential effects of the epidermal growth factor receptor (EGFR) inhibition in transitional cell carcinoma and to determine the effect of neoadjuvant erlotinib on gene expression. Tumor tissue is also evaluated by real-time polymerase chain reaction to confirm drug effects on expected targets and on EGFR expression, activity, and affected signaling pathways in the disease state and by microarray analysis to define expression phenotypes correlating with outcome, distinguish responders from nonresponders, and determine effects of drug treatment on gene expression in disease.
Patients are followed periodically for up to 5 years after surgery.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed muscle-invasive bladder cancer, meeting the following criteria:
- Clinical stage T2 disease
- No locally-extensive clinical stage T3 or T4 disease
- No metastatic disease (N+, M+) by physical exam or radiologic evaluation
- Must have undergone prior initial or confirmatory transurethral resection of the bladder tumor (TURBT)
- Candidate for and has agreed to undergo radical cystectomy with curative intent
- No non-transitional cell carcinoma histologies
PATIENT CHARACTERISTICS:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Granulocyte count > 1,500/mm³
- Platelet count > 100,000/mm³
- Bilirubin normal
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times upper limit of normal
- Creatinine normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No contraindication to erlotinib hydrochloride or other tyrosine kinase inhibitors
PRIOR CONCURRENT THERAPY:
No prior radiotherapy or systemic chemotherapy for bladder cancer
- Prior single-dose mitomycin C allowed at the time of TURBT
- Prior 6- or 12-week course of adjuvant intravesical Bacillus Calmette-Guerin (BCG) therapy with or without recombinant interferon alfa-2a allowed
- At least 4 weeks since other prior or concurrent radiotherapy, chemotherapy, or hormonal therapy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Erlotinib
erlotinib given before and after transurethral resection of a bladder tumor, TURBT
|
Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy.
In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
Andere Namen:
Will occur 4 weeks prior to dosing with erlotinib
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib
Zeitfenster: 4 weeks before treatment and 4 weeks post treatment
|
Determine the effect of neoadjuvant erlotinib hydrochloride on histopathological, molecular, and genetic correlates in patients undergoing radical cystectomy for muscle-invasive bladder cancer.
Gene expression of pre-treatment and post-treatment tumor samples were analyzed to define molecular determinants of response or resistance to epidermal growth factor receptor (EGFR) inhibition.
Both in vitro and in vivo EGFR-associated signatures were evaluated on pre-treatment bladder tumors.
Candidate molecular determinants of sensitivity to EGFR inhibition were characterized and examined for their ability to predict sensitivity to EGFR inhibitors in vitro.
|
4 weeks before treatment and 4 weeks post treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Pathological Complete Response Rate
Zeitfenster: 4 weeks
|
Determine the pathological complete response rate (P0 rate) after undergoing radical cystectomy (RC).
Evaluated using Response Evaluation Criteria In Solid Tumors (RECIST).
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
4 weeks
|
Disease Recurrence and Progression Rates After Cystectomy
Zeitfenster: 2 years
|
To determine disease recurrence/progression rates after cystectomy in patients treated with erlotinib
|
2 years
|
Overall Survival Rate
Zeitfenster: 25 months
|
The number of patients who remained alive and with no evidence of disease at the mean (range) follow-up of 24.8 months (3.0-36.6).
|
25 months
|
Number of Subjects Experiencing Adverse Events
Zeitfenster: 4 weeks - 2 years following surgery
|
The incidence of all toxicities observed during neoadjuvant and adjuvant treatment phase.Toxicity will be graded per the Common Terminology Criteria for Adverse Events (CTCAE) 2.0.
|
4 weeks - 2 years following surgery
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Raj S. Pruthi, MD, UNC Lineberger Comprehensive Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Urologische Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Urologische Erkrankungen
- Erkrankungen der Harnblase
- Neoplasien der Harnblase
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Proteinkinase-Inhibitoren
- Erlotinib-Hydrochlorid
Andere Studien-ID-Nummern
- LCCC 0521
- P30CA016086 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California und andere MitarbeiterAbgeschlossenNicht kleinzelliges LungenkarzinomVereinigte Staaten
-
PfizerAbgeschlossenKarzinom, nicht-kleinzellige LungeVereinigte Staaten
-
Merck Sharp & Dohme LLCAbgeschlossen
-
Grupo de Investigación Clínica en Oncología RadioterapiaAbgeschlossenPlattenepithelkarzinom des Kopfes und HalsesSpanien
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.AbgeschlossenKarzinom, nicht-kleinzellige LungeVereinigte Staaten
-
PharmaMarAbgeschlossenFortgeschrittene bösartige solide TumorenSpanien, Vereinigte Staaten
-
Tragara Pharmaceuticals, Inc.AbgeschlossenWiederkehrender nicht-kleinzelliger LungenkrebsVereinigte Staaten
-
New Mexico Cancer Care AllianceAbgeschlossenFortgeschrittene Malignome solider TumoreVereinigte Staaten
-
PfizerAbgeschlossenNicht-kleinzelligem LungenkrebsVereinigte Staaten, Korea, Republik von, Vereinigtes Königreich, Griechenland, Slowakei, Frankreich, Belgien, Irland, Japan, Spanien, China, Schweden, Indien, Ungarn, Schweiz, Russische Föderation, Deutschland, Mexiko, Dänemark und mehr
-
SCRI Development Innovations, LLCBayerAbgeschlossenNicht-kleinzelligem LungenkrebsVereinigte Staaten